CD4 enumeration technologies: a systematic review of test performance for determining eligibility for antiretroviral therapy. by Peeling, Rosanna W et al.
Peeling, RW; Sollis, KA; Glover, S; Crowe, SM; Landay, AL; Cheng,
B; Barnett, D; Denny, TN; Spira, TJ; Stevens, WS; Crowley, S; Es-
sajee, S; Vitoria, M; Ford, N (2015) CD4 enumeration technologies:
a systematic review of test performance for determining eligibility for
antiretroviral therapy. PLoS One, 10 (3). e0115019. ISSN 1932-6203
DOI: 10.1371/journal.pone.0115019
Downloaded from: http://researchonline.lshtm.ac.uk/2131860/
DOI: 10.1371/journal.pone.0115019
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/about/pdm
RESEARCH ARTICLE
CD4 Enumeration Technologies: A
Systematic Review of Test Performance for
Determining Eligibility for Antiretroviral
Therapy
RosannaW. Peeling1*, Kimberly A. Sollis1, Sarah Glover1, Suzanne M. Crowe2, Alan
L. Landay3, Ben Cheng4, David Barnett5, Thomas N. Denny6, Thomas J. Spira7, Wendy
S. Stevens8, Siobhan Crowley9, Shaffiq Essajee10, Marco Vitoria11, Nathan Ford11
1 London School of Hygiene and Tropical Medicine, London, WC1E 7HT, England, 2 Centre for Biomedical
Research, Burnet Institute, Melbourne, 3004, Victoria, Australia, 3 Department of Immunology/Microbiology,
Rush University Medical Center, Chicago, IL, 60612, United States of America, 4 Pangaea Global AIDS
Foundation, Oakland, CA, 94607, United States of America, 5 UK NEQAS for Leucocyte
Immunophenotyping, Sheffield, S10 2QD, England, 6 Duke Human Vaccine Institute and Center for HIV/
AIDS, Immunology and Virology Quality Assessment Center, Durham, NC, 27710, United States of America,
7 Division of AIDS, STD, &TB Laboratory Research, National Center for Infectious Diseases, Centers for
Disease Control and Prevention, Atlanta, GA, 30333, United States of America, 8 University of the
Witwatersrand, Parktown, 2193, South Africa, 9 Director Health Programs, ELMA Philanthropies, New York,
NY, United States of America, 10 Clinton Health Access Initiative, Boston, MA, 02127, United States of
America, 11 World Health Organization, Geneva, Switzerland
* rosanna.peeling@lshtm.ac.uk
Abstract
Background
Measurement of CD4+ T-lymphocytes (CD4) is a crucial parameter in the management of
HIV patients, particularly in determining eligibility to initiate antiretroviral treatment (ART). A
number of technologies exist for CD4 enumeration, with considerable variation in cost, com-
plexity, and operational requirements. We conducted a systematic review of the perfor-
mance of technologies for CD4 enumeration.
Methods and Findings
Studies were identified by searching electronic databases MEDLINE and EMBASE using a
pre-defined search strategy. Data on test accuracy and precision included bias and limits of
agreement with a reference standard, and misclassification probabilities around CD4
thresholds of 200 and 350 cells/μl over a clinically relevant range. The secondary outcome
measure was test imprecision, expressed as % coefficient of variation. Thirty-two studies
evaluating 15 CD4 technologies were included, of which less than half presented data on
bias and misclassification compared to the same reference technology. At CD4 counts
<350 cells/μl, bias ranged from -35.2 to +13.1 cells/μl while at counts>350 cells/μl, bias
ranged from -70.7 to +47 cells/μl, compared to the BD FACSCount as a reference technolo-
gy. Misclassification around the threshold of 350 cells/μl ranged from 1-29% for upward
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Conclusions
A wide range of bias and percent misclassification around treatment thresholds were re-
ported on the CD4 enumeration technologies included in this review, with few studies re-
porting assay precision. The lack of standardised methodology on test evaluation, including
the use of different reference standards, is a barrier to assessing relative assay perfor-
mance and could hinder the introduction of new point-of-care assays in countries where
they are most needed.
Introduction
The increased availability of antiretroviral therapy (ART) has resulted in major reductions in
morbidity and mortality in high HIV burden settings. Through significant global scale-up, ac-
cess to ART is increasing, with around 10 million people in low- and middle-income settings
receiving treatment as of the end of 2013, an estimated 65% of the of the global target of 15 mil-
lion people set for 2015 [1].
CD4+ T-lymphocytes, also known as the helper T-cells, are the coordinators of the immune
response that protects the body against microbial disease, a variety of autoimmune diseases
and some forms of cancer. The destruction of CD4+ T-lymphocytes by HIV is the main cause
of the progressive weakening of the immune system in HIV infection, and leads ultimately to
acquired immune deficiency syndrome (AIDS). The CD4 count is a strong predictor of HIV
progression to AIDS and death, and is considered the best laboratory marker for deciding
when to initiate ART [2,3]. The use of clinical staging alone to determine the timing of ART
initiation is limited by the unreliable correlation between asymptomatic or mild disease and
short-term prognosis and may result in dangerous delays in treatment initiation in those with-
out symptoms but with severe immune suppression [4].
Prior to 2013, the World Health Organization (WHO) recommended ART initiation in
all HIV-infected individuals whose CD4 count has dropped to350 cells/μl, irrespective of
clinical symptoms. The WHO 2013 guidelines have raised the threshold for ART initiation to
500 cells/μl, with priority given to those with a CD4 count to350 cells/μl, consistent with
emerging data, indicating a clinical and public health benefit of earlier treatment and as part of
a global effort to get 15 million HIV patients on ART by end of 2015 [5].
A number of technologies are available for CD4 enumeration, with considerable variation
in cost, complexity, and operating requirements (Tables 1–5). The traditional approach to cal-
culating absolute CD4+ T lymphocyte counts is to use the total leukocyte count (or lymphocyte
count) obtained from the hematology analyzer and then use the percentage CD4+ T lympho-
cytes from the flow cytometric analysis to calculate the absolute values—the so-called “dual
platform” (DP) approach. Quite often, however, two separate samples are used in the proce-
dure, one to obtain the total leukocyte count using a hematology analyzer and one to undertake
the flow cytometry, each having its own in-built variation. Thus, when the results from each
are combined to determine the absolute CD4+ T lymphocyte count, the variation is com-
pounded such that inter-laboratory variation between centers can be as high as 40%. Thus, the
need to derive accurate and precise absolute CD4+ T lymphocyte counts has led to the
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development of instruments that can produce both percentage and absolute values, termed
the”single platform” approach (SP).
Two SP approaches are in widespread use today: volumetric and bead based. The principle
of the volumetric approach is that a known volume of sample is passed through the flow cell
(and interrogated by the laser beam) in a known amount of time. The alternative approach is
Table 1. Operating characteristics of ﬂow cytometric methods for CD4+ T-cell enumeration, using conventional ﬂow cytometers.
FLOW CYTOMETRY USING CONVENTIONAL FLOW CYTOMETERa
Conventional dual platform Bead-based single platform technology on conventional ﬂow
cytometer
Panleucogating
Assay name Various Trucount tubes Flow-Count
beads
Perfect-Count PLG CD4
Manufacturer Various Becton Dickinson Beckman
Coulter
Cytognos Beckman Coulter
Compatible with various reagent systems and ﬂow cytometers Compatible with various
reagent systems and
ﬂow cytometers
Instrumentation Flow cytometer plus haematology
analyser
Flow cytometer Gating strategy
Assay principle Absolute count calculated using
results from ﬂow cytometry
together with the total lymphocyte
count from haematology analyser
Absolute CD4 counts determined using ratio of CD4 to a known
quantity of ﬂuorescent beads—no need for haematology analyser
Gating strategy using
total white cell count
Trucount tubes
contain premeasured
quantity of lyophilised
beads
Liquid beads
need accurate
pipetting by
operator
Two different bead
populations allow
detection of
inadequate mixing
Parameters
measured
Absolute CD4 and CD4% Absolute CD4 and CD4% Absolute CD4 and
CD4%
Others depend on reagent kits/
methods
Specimen 500μl whole blood in EDTA Up to 100μl whole blood in EDTA 100μl whole blood in
EDTA
Throughput Up to 250 samples/day Up to 250 samples/day Up to 250 samples/day
Compatible with
independent EQA/PT
programmes?
Yes Yes Yes Yes Yes
Is there access to
compatible full
process QC reagent?
Yes Yes Yes Yes N/A
Maximum length of
time from blood draw
to testing
24 hours 24 hours 5 days
Can the test be
performed on ﬁxed/
stabilised blood
Yes Yes Yes Yes Yes
Complexity/training
required
Complex. Signiﬁcant training
required.
Complex. Signiﬁcant training required Moderate training
requirement
Environmental/energy
issues
Requires uninterrupted mains
electricity
Requires uninterrupted mains electricity Requires uninterrupted
mains electricity
Robustness to heat/
humidity
Climate control recommended Climate control recommended Climate control
recommended
Reagents require refrigeration Reagents require refrigeration Reagents require
refrigeration
a Various ﬂow cytometers available from various manufacturers. Examples include Becton Dickinson FACSCalibur, Beckman Coulter Epics XL.
doi:10.1371/journal.pone.0115019.t001
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Table 2. Operating characteristics of dedicated single platform CD4+ T-cell enumeration systems.
DEDICATED SINGLE PLATFORM CD4 SYSTEMS
Assay name FACSCount Guava PCA Partec CyFlow Counter or
CyFLow SL_3
Apogee Auto40
Manufacturer Becton Dickinson Millipore (formerly Guava
Technologies and now a division
of Merck)
Partec Apogee ﬂow systems
Instrumentation Flow cytometer Flow cytometer Flow cytometer Flow cytometer
Assay principle Dedicated single platform
bead-based ﬂow
cytometer, two colour, no-
lyse no-wash
Single platform volumetric ﬂow
cytometer. Microcapillary ﬂow
cell. Previously used EasyCD4
reagents (EasyCD4 system),
since replaced by Auto CD4/
CD4%. Company also produces
the more complex easyCyte
instruments, for research use
only.
Volumetric SP ﬂow cytometer. Up
to 3 parameters (2 colour plus
SSC). Simplest is single
parameter CD4. For CD4%, 2
colour (CD45/4) + SSC. SL_3
(also called SL green) operates
on the same principles but is
adaptable to wider applications.
Other CyFlow instruments such
as SL blue have a wider range of
parameters and potential
applications.
Volumetric ﬂow cytometer
Parameters
measured
Absolute CD4 count and
CD4%
Absolute CD4 count and CD4% Absolute CD4 count and CD4% Absolute CD4 and CD4%
Specimen 50μl whole blood in EDTA 10μl whole blood in EDTA 20μl whole blood in EDTA 50μl whole blood in EDTA
Throughput 30 samples/hour, at CD4
counts400
100–150 samples/day 250 samples/day, 400 samples/
day with loader
20 samples/hour
Compatible with
independent EQA/
PT programmes?
Yes Yes Yes No data available
Is there access to
compatible full
process QC
reagent?
Yes No manufacturer-produced full
process control
Manufacturer produces dry
stabilised control blood
No manufacturer-produced
full process control
Maximum length of
time from blood draw
to testing
Stain within 48 hours of
draw (24 hours for CD4%)
(store at 20–25°C),
analyse within 48 hours of
staining.
48 hours 48 hours Preferably run within 6–8
hours unless stabilised
Can the test be
performed on ﬁxed/
stabilised blood
Yes Yes Yes Yes
Complexity/training
required
One day training One day training Moderate training requirement One day training
Environmental/
energy issues
Requires uninterrupted
mains electricity
Requires uninterrupted mains
electricity Less biohazardous
waste (reduced by 100 fold)
Mains electricity or car battery or
solar panels
UPS with battery back up
included. Optional inverter
allows instrument to be
powered by vehicle battery
Robustness to heat/
humidity
10–35°C, 5–95% non-
condensing humidity.
Reagents require
refrigeration.
Instrument: up to 35°C. 10–90%
non-condensing relative humidity.
Reagents require refrigeration.
Solid state laser more stable than
water or air cooled gas lasers at
high temperatures. Liquid
reagents require refrigeration, or
dry reagent kits available which
can be stored at up to 60°C in
dark for up to 12 months
Option of thermostable
reagents with 9 month shelf
life at room temperature.
Instrument: 5–35°C, <90%
humidity.
PCA = personal cell analysis, SSC = side scatter.
doi:10.1371/journal.pone.0115019.t002
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Table 3. Operating characteristics of manual technologies for CD4+ T-cell enumeration.
MANUAL METHODS
Assay name Coulter Manual CD4 Count Kit (Cytospheres) Dynal T4 Quant Kit (Dynabeads)
Manufacturer Beckman Coulter Invitrogen/Dynal Biotech
Instrumentation Light microscope, haemocytometer Fluorescent or light microscope, haemocytometer, magnet
Assay principle Inert latex spheres coated with monoclonal Ab form
rosettes on contact with CD4 cells—readily visible by
light microscopy
Magnetic polystyrene beads, coated with mouse monoclonal Ab,
allow isolation of CD4+ T cells followed by counting using
ﬂuorescent (preferable) or light microscope
Parameters measured Absolute CD4 count Absolute CD4 count
Specimen 100μl whole blood in EDTA 125μl whole blood in EDTA or ACD
Throughput 10 samples/day. Operator fatigue a limitation.
Suggest stop counting at 500 cells. Batch size limited
to 2 samples
10 samples/day. Operator fatigue a limitation. Suggest stop
counting at 500 cells. Batch size limited to 6 samples
Compatible with independent
EQA/PT programmes?
No No
Is there access to compatible
full process QC reagent?
No No
Maximum length of time from
blood draw to testing
72 hours at 20°C 72 hours at 20°C
Can the test be performed on
ﬁxed/ stabilised blood
No Compatible with Cyto-Chex (Streck, USA) stabilised refrigerated
samples up to 9 days after collection. Not compatible with
TransFix (CytoMark, UK).
Complexity/training required 1–3 days training 1–3 days training
Environmental/energy issues Requires power for microscope Requires power for microscope
Robustness to heat/humidity Reagents need refrigeration Reagents need refrigeration
doi:10.1371/journal.pone.0115019.t003
Table 4. Operating characteristics of other commercially available technologies for CD4+ T-cell enumeration.
OTHER COMMERCIALLY AVAILABLE TECHNOLOGIES
Assay name PocH-100i/KX-21N with Dynal Dynabeads CD4 Select
Manufacturer Sysmex i+MED Laboratories Co. Ltd.
Instrumentation Haematology analyser Haematology analyser, magnet, rotator
Assay principle CD4 cell isolation using modiﬁed Dynal dynabeads,
counting using haematology analyser with speciﬁc
software
Ferrous beads coated with MT4 mAb bind to CD4 T cells, which
are then removed using magnet. Whole blood and CD4-deplete
blood counted on haematology analyser. CD4 count and %
calculated using established formulae
Parameters measured Absolute CD4 count and CD4% Absolute CD4 and CD4%
Specimen 125 μl whole blood in EDTA 400μl whole blood in EDTA
Throughput 12 samples/hour No data available
Compatible with independent
EQA/PT programmes?
No EQA evaluation data available No EQA evaluation data available
Is there access to compatible
full process QC reagent?
No data available No data available
Maximum length of time from
blood draw to testing
24 hours at 4 or 20°C No data available
Can the test be performed on
ﬁxed/ stabilised blood
No data available No data available
Complexity/training required Moderate complexity Moderate complexity
Environmental/energy issues Requires power for haematology analyser Requires power for haematology analyser and rotator
Robustness to heat/humidity No data available No data available
doi:10.1371/journal.pone.0115019.t004
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to use bead-based technologies where a known number of beads is added to a known volume
of sample thus allowing calculation of the bead to cell ratio and the subsequent calculation of
the absolute cell count, in this instance, CD4+ T lymphocytes. An important feature of any ab-
solute counting system is pipetting accuracy and minimum sample manipulation. The intro-
duction of SP technologies has had a beneficial effect and lowered inter-laboratory variation in
CD4 enumeration.
It is critical that country programmes consider whether these tests can give accurate and re-
producible results as well as being appropriate for the setting [6]. In particular, we focussed on
how bias and misclassification probabilities of different CD4 assays may affect eligibility for
ART initiation. Misclassification probabilities give clinically useful measures of test perfor-
mance and should be reported in evaluations of CD4 technologies. An upward misclassifica-
tion around a treatment threshold means that a patient who should be eligible for treatment
would be denied treatment, while a downward misclassification would not lead to ineligibility
for treatment. To date, there have been no systematic reviews of the performance of CD4 tech-
nologies. Here we provide an evaluation of the performance characteristics of CD4 technolo-
gies through a systematic review of published literature.
Methods
We performed a systematic review of studies evaluating the performance of CD4 enumeration
technologies. A search of the Cochrane Library and the Centre for Reviews and Dissemination
Table 5. Operating characteristics of Point of Care (POC) technologies for CD4+ T-cell enumeration.
POINT OF CARE TECHNOLOGIES
Assay name PointCare NOW Pima CyFlow miniPOC
Manufacturer PointCare Technologies Alere (formerly Inverness Medical) Partec
Instrumentation Point of care instrument Point of care instrument Point of care instrument
Assay principle CD4 and haematology contained in one unit. All test reagents sealed within
disposable cartridge.
Compact ﬂow cytometric
device. Uses dry reagents
Gold nanoparticles conjugated to CD4 antibodies
(no ﬂuorescence). LED light source.
Portable analyser uses static image
analysis and cell counting principles
Parameters measured Absolute CD4, CD4%, Hb, differential white cell
count
Absolute CD4 Absolute CD4 and CD4%
Specimen 40μl whole blood in EDTA 25μl capillary or venous blood 20μl whole blood in EDTA
Throughput 50 samples/day 3 samples/hour 250 samples/day
Compatible with independent
EQA/PT programmes?
No Under investigation Compatible with German
EQA programme
Is there access to compatible
full process QC reagent?
No data available No data available Company produce dry
stabilised blood samples for
QC
Maximum length of time from
blood draw to testing
8 hours 24 hours Provisional data suggest 24
hrs
Can the test be performed on
ﬁxed/ stabilised blood
No data available Compatible with Transﬁx (CytoMark,
UK)
No data available
Complexity/training required Moderate Minimal Moderate
Environmental/energy issues Requires mains or battery power Requires mains or battery power Requires mains or battery
power
Robustness to heat/humidity Reagents do not require refrigeration.
Instrument: 18–34°C, <80% relative humidity,
non-condensing
No refrigeration required (dried
reagents)
No refrigeration required
(dried reagents)
doi:10.1371/journal.pone.0115019.t005
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databases, including the Database of Abstracts of Reviews of Effects (DARE), the National
Health Service Economic Evaluation Database (NHS EED) and the National Institute for
Health Research Health Technology Assessment (NIHR HTA) database found no existing re-
views addressing the review objective.
We followed standard guidance in performing the review [7]. Objectives and methods of
the review were documented in a review protocol, which is included as S1 Methods.
Eligibility criteria
Eligibility criteria were defined using the PICOS (Population, Interventions, Comparisons,
Outcomes, Study Design) format. Studies evaluating the accuracy and/or precision of any CD4
technology commercially available at the time of the review were considered eligible for inclu-
sion. Currently, no “gold” standard technology or internationally recognised reference prepara-
tion exists for CD4 enumeration, and a wide range of flow cytometric technologies have been
used as comparators [6].
For the purposes of this review, we included studies that used as reference technologies any
flow cytometric method considered to be acceptable by the WHO HIV diagnostics working
group named in the review protocol (S1 Methods).
Information Sources
Studies were identified by searching two electronic databases—MEDLINE and EMBASE, scan-
ning the reference lists of the Nature supplement Evaluating diagnostics: the CD4 guide, and by
inviting the WHO working group, whose members are authors of the Nature supplement to
identify relevant studies for the review [6,8].
Search Strategy
We used the following search terms to search the electronic databases: “CD4”, “technolog”,
“methodolog”, “techn”, “method”, “test”, “evaluation”, “validation”, “accuracy”, “compari-
son”, “efficacy”, “performance”, “reproducibility”, “precision”, “flow AND cytometry”. Subject
headings included: “CD4 antigen”, “antigens, CD4”, “CD4 lymphocyte count”, “CD4-positive
T-lymphocytes”, “technology”, “methodology”, “technique”, “evaluation”, “clinical evaluation”,
“economic evaluation”, “evaluation research”, “evaluation and follow up”, “instrument valida-
tion”, “validation process”, “validation study”, “evaluation studies as topic”, “validation stud-
ies”, and “flow cytometry”. Full electronic search strategies and review protocols are detailed in
S1 Methods.
Study selection
Articles were exported from the search database to EndNote and screened for relevance
(Fig. 1). Data were extracted by two independent reviewers (SG and KS) and disagreements re-
solved through consensus.
Data extraction
The following data were extracted: study location, index test, reference test, and population
(HIV positive or HIV positive and negative). Data on accuracy and precision included bias or
mean difference and limits of agreement, misclassification probabilities (when sensitivity or
specificity values were given, misclassification probabilities were calculated), and coefficient of
variation. Where possible, HIV positive data alone were extracted. Where this was not possible,
CD4 Assay Performance: A Systematic Review
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Fig 1. PRISMA flow diagram of study selection. EQA: external quality assurance, FC: flow cytometry.
doi:10.1371/journal.pone.0115019.g001
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combined HIV positive and negative data were extracted. Only data within the clinically rele-
vant range (thresholds of 200, 350, 500 cells/μl) were extracted as per the inclusion criteria.
Studies should report not only percent misclassification around clinically important CD4
cell thresholds (e.g., 200, 350 or 500 cells/μl), but should also report the magnitude of
these misclassifications.
The secondary outcome measure addressed precision or reproducibility. Precision is partic-
ularly important when following a patient’s serial measurements using the same technology.
Precision can be measured within-laboratory or between-laboratories and is expressed as per-
cent coefficient of variation (%CV).
Studies meeting inclusion criteria were also assessed for bias and quality on ten points
drawn from the STARD guidelines (Fig. 2) [9]. This review has been reported following the
PRISMA statement guidance for reporting of systematic reviews [10,11].
Results
A summary of different commercially available CD4 technologies, including their assay princi-
ples, operational characteristics and compatibility with international external quality assurance
programme reagents, is shown in Tables 1–5. Conventional flow cytometry based technologies
include DP technologies such as the BD FACSCalibur (BD Biosciences, a division of Becton
Dickinson, Franklin Lakes, NJ, USA [BD]) and the Epics XL (Beckman Coulter, Inc., Pasadena,
CA, USA [BC]); bead-based SP technologies such as the BD Trucount Tube, the BC Flow
Count Tubes, the Cytognos Perfect Count (Cytognos S.L., Salamanca, Spain [Cytognos]), and
the BC Pan-leucogating (PLG) FlowCare CD4. Dedicated SP CD4 technologies include bead-
based BD FACSCount, and three volumetric assays, Millipore Guava PCA (EMDMillipore,
Darmstadt, Germany [Guava]), Partec CyFlow Counter (Partec, a division of Sysmex, Corpo-
ration, Kobe, Japan [Partec]) and Apogee Auto40 Flow Cytometer (Apogee Flow Systems,
Hertfordshire, UK [Apogee]). There are two manual microscopy based counting methods, the
BC Cytospheres and the Dynal T4 Quant (Dynal Biotech ASA, a division of Thermo Fisher Sci-
entific Inc., Waltham, MA, USA [Dynal]). Point-of-care (POC) analysers include the Sysmex
pocH-100i with Dynabeads from Dynal, the i+MED CD4 Select (i+ MED Laboratories, Bang-
kok, Thailand [i+ MED]), the Pima Analyzer (Alere Inc., Waltham, MA, USA [Alere]), and
PointCare NOW (PointCare Technologies, Marlborough, MA, USA [PointCare]).
Study selection
This systematic review was first performed in July 2009. Of the 433 studies in the search, 345
were excluded as they were not performance evaluations. After further triage, 20 studies that
measured bias, misclassification and/or %CV were accepted for inclusion in this review
(PRISMA flow diagram, Fig. 1). A second search was conducted in April 2013 using the same
search strategy and review protocol with the goal of capturing more POC CD4 enumeration
technologies in the review. An additional 12 studies were included. A summary of data ex-
tracted from all eligible studies with data on bias, misclassifications and/or %CV is shown in
S1 Dataset.
Study characteristics
A summary of study characteristics is shown in Table 6.
At least one published performance evaluation study was found for each of the following
technologies: BC Cytospheres [12–18], Dynal Dynabeads [14,18–22], Guava PCA [23–29],
Partec CyFlow instruments [16,26,30–36], BD FACSCount [14,37–42]; BD Trucount tubes
[43–46], BC Flow-Count fluorospheres [47], Cytognos Perfect-Count microspheres [48], SP
CD4 Assay Performance: A Systematic Review
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Fig 2. Methodological quality of included studies. EQA: external quality assurance, IQC: internal
quality control.
doi:10.1371/journal.pone.0115019.g002
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Table 6. Characteristics of included studies.
Study Location Laboratory or
healthcare level
at which the
study was
performed
Reference
standard
Index test (test
under evaluation)
Population No. of samples
used in
accuracy
studies (n)
Balakrishnan 200412 Chennai, India Charitable
foundation clinical/
research lab
BD FACSCount Coulter
Cytospheres
HIV pos 122
Carella 199513 USA Teaching hospital /
research lab?
DP FC Coulter
Cytospheres
HIV pos and neg 117
Landay 199317 USA and Uganda University research
hospitals
DP FC Coulter
Cytospheres
HIV pos and neg 382
Gernow 199515 Denmark and
Ivory Coast
Not clear DP FC Coulter
Cytospheres
HIV pos and neg 123
Didier 200114 Paris Teaching hospital
lab
SP FC using BD
Trucount tubes
Coulter
Cytospheres
HIV pos and neg 55
SP FC using BD
Trucount tubes
Dynal Dynabeads HIV pos and neg 46
SP FC using BD
Trucount tubes
BD FACSCount HIV pos and neg 45
Karcher 200616 Uganda Local lab, ﬁeld
conditions
DP FC Coulter
Cytospheres
HIV pos 131, from 102
donors
DP FC Partec CyFlow
Counter CD4/SCC
NLNW
HIV pos 128 from 121
donors
Lutwama 200818 Uganda University
laboratory
BD FACSCount or
FACSCalibur
Coulter
Cytospheres
HIV pos 1444 (497
donors)
BD FACSCount or
FACSCalibur
Dynal Dynabeads HIV pos 1671
Diagbouga 200319 Five countries in
West Africa
Local laboratories SP FC using BD
Trucount tubes
Dynal Dynabeads HIV pos 657, from 301
donors
Imade 200521 Nigeria University hospital
laboratory
Partec CyFlow Dynal Dynabeads HIV pos and neg 40
Idigbe 200620 Nigeria Research
laboratory
BD FACSCount Dynal Dynabeads HIV pos and neg 97 (46 HIV pos,
51 neg)
Balakrishnan 200623 Chennai, India Charitable
foundation clinical/
research lab
BD FACSCount Guava Easy CD4 HIV pos and neg 228
Kandathil 200524 South India Medical college
laboratory and
charitable
foundation clinical/
research laboratory
BD FACSCount Guava Easy CD4 HIV pos and neg 72 (51 HIV pos,
21 neg)
Spacek 200628 United States University
laboratory
DP FC Guava Easy CD4 HIV pos 77
Uganda University
laboratory
BD FACSCount Guava Easy CD4 HIV pos 141
Thakar 200629 Pune, India Research institute DP FC Guava Easy CD4 HIV pos 79
Pattanapanyasat
200725
Bangkok, Thailand Teaching hospital
laboratory and
ministry of public
health-cdc lab
SP FC using BD
Trucount tubes
Guava Easy CD4 HIV pos 250
BD FACSCount Guava Easy CD4 HIV pos 250
Pattanapanyasat
200826
Thailand Teaching hospital
laboratory
SP FC using BD
Trucount tubes
Guava Easy CD4 HIV pos 150
(Continued)
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Table 6. (Continued)
Study Location Laboratory or
healthcare level
at which the
study was
performed
Reference
standard
Index test (test
under evaluation)
Population No. of samples
used in
accuracy
studies (n)
BD FACSCount Guava Easy CD4 HIV pos 150
SP FC using BD
Trucount tubes
Partecv CyFlow
SL_3
HIV pos 150
BD FACSCount Partec CyFlow
SL_3
HIV pos 150
Renault 201027 Burkina Faso Community
laboratory
BD FACSCount Guava Easy CD4 HIV pos 98
Zijenah 200636 Zimbabwe University
laboratories
BD FACSCount Partec CyFlow
Counter
HIV pos 150
Fryland 200632 Malawi District hospital
laboratory
BD FACSCount Partec CyFlow
Counter
HIV pos and neg 311 (276 HIV
pos, 35 HIV neg)
Cassens 200430 Africa and Asia ‘Hospital
laboratories’
Various Partec CyFlow SL
(SCC + CD4),
NLNW
HIV pos and neg 434
Pattanapanyasat 2005
‘Evaluation of a new.’
52
Bangkok, Thailand Teaching hospital
laboratory
SP FC using BD
Trucount tubes
Partec CyFlow
SL_3 (using single
parameter CD4)
HIV pos 200
BD FACSCount Partec CyFlow
SL_3 (using single
parameter CD4)
HIV pos 200
Manasa 200734 Zimbabwe National reference
laboratory
DP FC Partec CyFlow
SL_3 (SCC +CD4
+CD45) (absolute
CD4 and %CD4)
HIV pos 229
Dieye 200531 Senegal Laboratory of a
University Hospital
SP FC using BD
Trucount tubes
Partec CyFlow SL
Blue CD45/CD3/
CD4 + SCCLNW
HIV pos and neg 121 (102 HIV
pos donors, 28
neg)
BD FACSCount Partec CyFlow SL
Blue CD45/CD3/
CD4 + SCCNLNW
121 (102 HIV
pos donors, 28
neg)
Lynen 200633 Cambodia Laboratory of an
NGO-run hospital
BD FACSCount Partec CyFlow
SL_3 CD4+SSC
LNW manual gating
‘Likely to be HIV
positive’
115
Strauss 199642 Belgium, UK,
USA, Spain
Research
laboratories,
teaching hospital
laboratory and
manufacturer
DP FC BD FACSCount HIV pos and neg
Lopez 199939 Spain and
Portugal
7 centres: 6
hospital
laboratories and
one University
laboratory
BD FACScan BD FACSCount HIV pos and neg 49 (37 HIV pos,
12 HIV neg)
Johnson 199538 USA University
laboratory?
DP FC BD FACSCount HIV pos and neg 47
Nicholson 199440 USA Government
laboratory
DP FC BD FACSCount Unknown for
accuracy studies
50
Lyamuya 199622 Tanzania Teaching hospital
laboratory?
DP FC BD FACSCount HIV pos and neg 173
DP FC Dynal Dynabeads HIV pos and neg 189
(Continued)
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Table 6. (Continued)
Study Location Laboratory or
healthcare level
at which the
study was
performed
Reference
standard
Index test (test
under evaluation)
Population No. of samples
used in
accuracy
studies (n)
Bergeron 201037 Morocco/Canada National reference
laboratories
BD FACSCount BD FACSCount
using Rea T Count
dry reagents
HIV pos 167
BD FACSCalibur BD FACSCount
using Rea T Count
dry reagents
HIV-pos 80
Sitoe 201141 Mozambique Not stated BD FACSCount
using venous blood
BD FACSCount
using capillary
blood
HIV pos 101 adults
BD FACSCalibur
using venous blood
BD FACSCalibur
using capillary
blood
HIV pos 101 adults
Schnizlein-Bick 200046 USA 5 NIAID certiﬁed
FC laboratories
DP FC SP FC using BD
Trucount tubes
HIV pos 60 common
samples shipped
to 5 sites, plus
14 local donors
at each of 5 sites
Nicholson 199745 USA University
laboratory
DP FC SP FC using BD
Trucount tubes
HIV pos and neg 81
Higgins 200743 USA Research
laboratory
DP FC SP FC using BD
Trucount tubes
HIV pos 25
Jeganathan 200844 Australia Central laboratory DP FC SP FC using BD
Trucount tubes
HIV pos 60 paired
samples from 18
patients
Reimann 200047 USA 5 clinical FC
laboratories
DP FC SP FC using BC
Flow-Count
ﬂuorospheres: two
colour + ﬂow count
HIV pos 14 from each
of 5 local sites =
71, plus 67
central
specimens
DP FC SP FC using BC
Flow-Count
ﬂuorospheres:
tetraONE system
HIV pos 14 from each
of 5 sites = 71,
plus 71 central
specimens
Storie 200448 UK Teaching hospital
laboratory?
SP FC using BD
Trucount tubes
SP FC using
Cytognos Perfect-
Count beads
HIV pos 104
Storie 200349 UK Teaching hospital
laboratory?
SP FC with BD
Trucount tubes
SP FC using ﬂow
rate calibration
HIV pos 113
SP FC with BD
Trucount tubes
DP PLG HIV pos 113
Denny 200850 USA 5 FC laboratories Varied by lab—SP
or DP FC
DP PLG HIV pos 99 samples sent
to 5 labs, plus 58
local samples
Pattanapanyasat 2005
‘A multicentre
evaluation.’ 35
Thailand 2xteaching hospital
labs, 2xregional
hospital labs
DP FC DP PLG HIV pos 611
Glencross, 200251 Johannesburg,
South Africa
Teaching hospital
laboratory
DP FC DP PLG Not stated 183
Volumetric SP FC DP PLG Not stated 112
SP FC using BD
Trucount tubes
DP PLG Not stated 112
(Continued)
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Table 6. (Continued)
Study Location Laboratory or
healthcare level
at which the
study was
performed
Reference
standard
Index test (test
under evaluation)
Population No. of samples
used in
accuracy
studies (n)
Sippy-Chatrani 200853 Barbados National HIV
laboratory
SP FC with BC
Flow-Count
ﬂuorospheres
SP PLG using BC
FlowCARE
HIV pos 153
Briggs 200954 UK laboratory SP FC Sysmex PocH-100i
with Dynal
Dynabeads
HIV positive for
accuracy studies,
HIV positive/
leukaemia
/lymphoma for
precision
115
Srithanaviboonchai
200855
Thailand Research lab? DP FC i+MED CD4 select HIV positive 100
Mtapuri-Zinyowera
201057
Zimbabwe VCT clinic SP FC using BD
Trucount tubes
Alere Pima using
capillary blood
HIV pos 165
Jani 201156 Mozambique Primary healthcare
clinics
BD FACSCalibur Alere PIMA using
capillary and
venous blood
HIV pos 135
Sukapirom 201158 Thailand Teaching hospital
laboratory
BD FACSCount Alere PIMA using
venous blood
HIV pos 203
Manabe 2012 Uganda Tertiary hospital
laboratory
BD FACSCalibur
with TruCount
beads
Alere PIMA using
capillary and
venous blood
HIV pos 380
Herbert 201361 UK Hospital laboratory
(HIV service)
Coulter FC 500 Alere PIMA using
capillary and
venous blood
HIV pos 283
Bergeron 201260 Belgium, Canada,
Mozambique,
South Africa, USA
National
laboratories
BD FACSCalibur,
except in South
Africa where the
BC Epics-XL was
used
PointCare NOW HIV pos and neg 472
Logan 201362 USA Research
laboratory
BD FACSCalibur mBio Snap Count
using capillary and
venous blood
HIV pos 146
Mbopi-Keou 201263 Cameroon National Health
Laboratory
BD FACSCalibur Apogee Auto40
Flow Cytometer
HIV pos and neg 234 (adults and
children)
Mbopi-Keou 201264 Cameroon HIV reference
Laboratory
BD FACSCalibur Apogee Auto40
Flow Cytometer
volunteers 257 (adults and
children)
FC = ﬂow cytometry.
DP = dual platform.
SP = single platform.
SCC = side scatter.
BD = Becton Dickinson.
BC = Beckman Coulter.
LNW = lyse, no-wash.
NLNW = no-lyse, no-wash.
VCT = Voluntary Counselling and Testing.
doi:10.1371/journal.pone.0115019.t006
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Flow Cytometry using flow rate calibration [49–52]; BC PLG FlowCARE CD4 [53], Sysmex
PocH-100i with Dynal Dynabeads [54], i+MED CD4 Select [55], Alere Pima Analyzer [56–
58,61], PointCare NOW [60], Apogee Auto40 [59,63,64] and MBio Snap Count (MBio Diag-
nostics, Inc., Boulder, CO, USA [MBio]) [62].
No published, peer-reviewed performance evaluations of the commercially available tech-
nology Partec miniPOC were found by our literature search, and the MBio assay is not yet
commercially available.
Methodological quality of included studies
The findings of the quality assessment of included studies are summarised in Fig. 2. Most stud-
ies reported the index test (test under evaluation) and the reference standard in sufficient detail
to be reproduced, but few studies reported whether staff at the evaluation sites were proficient
at performing the reference standard and/or sufficiently trained on performing the index test.
Few studies reported internal quality controls being performed during the evaluation period.
Without these quality measures, it would be difficult to differentiate whether the bias or mis-
classification between the index and reference tests was due to differences in inherent test char-
acteristics or to operator error.
Manufacturer involvement was evident in a number of studies. Seven studies declared one
or more authors to be affiliated with the manufacturer of the index test [12,17,39,42,46,54].
Four studies were partially sponsored by the manufacturer [25,26,45,53]. One study stated that
the manufacturer’s site was one of the study sites [42], and four studies declared donation of re-
agents or equipment by the manufacturer [15,29,38,40]. A further four studies could be consid-
ered to be calibration or test developers’ papers [30,49,51,55]. In the absence of definitions for
a sponsored study versus an independent evaluation, it is not clear to what extent the inclusion
of manufacturers as co-authors of papers influenced the study results.
Accuracy
As there is no international standard for CD4 enumeration, a variety of reference standard
technologies were used for evaluating the performance of new CD4 technologies, making it dif-
ficult to pool data on bias and misclassification across all studies.
Bias
Bias (mean difference) data were collated and represented graphically but only from studies
that compared the index tests mean difference to the same reference technology (Table 6 and
Fig. 3a, b). FACSCount and FACSCalibur were the most common reference technologies.
Bias was evaluated at CD4 thresholds of 200 cells/μl and 350 cells/μl using the BD FACS-
Count as a reference method. For the Pima Analyser, at CD4 counts at both<350 cells/μl and
>350 cells/μl, the studies found that the Pima Analyser consistently underestimated CD4
counts by-16.6 cells/μl (limits of agreement-88.4, +55.3 cells/μl at<350 cells/μl) and at-70.7
cells/μl (limits of agreement-216.5, +75 cells/μl) [58]. However, when the Guava Easy CD4 was
compared to the FACSCount, the bias for CD4 counts<350 cells/μl was +13 cells/μl (limits of
agreement-27, +53) and for cell counts>350 cells/μl, bias was-45.3 cells/μl [23,27].
The FACSCalibur, in comparison to the FACSCount, overestimated CD4 counts by +13.1
cells/μl at values of<350 cells/μl [41]. However, bias estimation of manual bead based methods
showed underestimation of CD4 counts at<350 cells/μl of-35.2 cells/μl (limits of agreement-
164.9,+ 94.6) and -0.4 cells/μl (limits of agreement-126, +125.2) for BC Cytospheres and Dynal
Dynabeads respectively [18].
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When the overall bias for all CD4 technologies was calculated, this ranged from-70.7 to +47
cells/μl for CD4 counts>350 cells/ μl and -35.2 to +13.1 cells/μl for CD4 counts<350 cells/μl
when compared to the FASCount as a reference method.
We then progressed to study bias data using a threshold of 200 cells/μl compared to FACS-
Count as a reference method. A total of six publications were identified covering the following
technologies, the Apogee Auto 40 [59], Guava Easy CD4 [23,25–27], and Partec CyFlow
Counter [26,52].
The four studies that had reported data at<200 cells/μl and compared the Guava Easy CD4
to the FACSCount, all had a positive bias that ranged from +10 to +45.5 cells/μl [23,25–27].
One study had data for CD4 counts>200 cells/μl and had a bias of +44.9 cells/μl (limits of
agreement-112.6 to + 212.3) [25]. It is interesting to note that all studies reporting the perfor-
mance of the Guava Easy CD4 showed that this assay overestimated CD4 counts compared to
the FACSCount [23,25–27].
Two studies compared the Partec CyFlow Counter to the FACSCount. One showed an
over-estimation by +0.8 cells/μl (limits of agreement-21.7 to +23.2) while the other showed an
underestimation by-5.8 cells/μl (limits of agreement-37.6 to +25.9) [26,52].
Overall when comparing the technologies to the FACSCount as a reference method, bias
ranged from +44.9 to -12.1 for CD4 counts>200 cells/ μl and +45.5 to -5.8 for CD4 counts
<200 cells/ μl. Bias using FACSCalibur as a reference method showed similar results to that
using FACSCount (Fig. 3a and b).
Misclassification
Fig. 4 showed the range of misclassifications at thresholds of 200 and 350 cells/μl of new CD4
assays compared to different reference standards.
Nine studies provided data on misclassification probabilities using a cut-off of 350 cells/μl
[16,18,27,56,60–64]. Data were available on the following assays: BC Cytospheres [16,18],
Dynal Dynabeads [18], Guava Easy CD4 [27], Partec CyFlow Counter [16], Pima Analyzer
[56,61], PointCare NOW [60], MBio Snap Count [62], and Auto40 Flow Cytometer [63,64].
Two studies [63,64] evaluated the Auto40 Flow Cytometer compared to the FACSCalibur in
Cameroon. One study [63] reported upward and downward misclassification probabilities of
Fig 3. A. Bias compared to FASCount as the reference technology. B. Bias compared to FASCalibur as the reference technology.
doi:10.1371/journal.pone.0115019.g003
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Fig 4. Misclassification (%), using a CD4 thresholds of 350 cells/μl and 200 cells/μl.
doi:10.1371/journal.pone.0115019.g004
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8% and 2%, respectively, while another [64] found the likelihood of under-treatment (upward
misclassification) to be 3% and the probability of over-treatment (downward misclassification)
to be 2%.
Karcher et al. conducted a large trial in field conditions in Uganda comparing BC Cyto-
spheres and the Partec CyFlow Counter to DP flow cytometry [16]. HIV positive patients were
recruited, the majority of whom had CD4 counts within a range from 0 to1200 (median 332
cells/μl). Of samples with CD4 counts<350 cells/μl measured by DP flow cytometry, BC Cyto-
spheres misclassified 16% of the patients as having CD4 counts of>350 cells/μl, thereby deny-
ing them of eligibility for treatment. Similarly for those with CD4 counts> 350 cells/μl
measured by DP flow cytometry, BC Cytospheres misclassified 20%, indicating that 20% of pa-
tients not qualifying for treatment using the reference test would have done so if BC Cyto-
spheres were used. Karcher et al. also compared the Partec CyFlow to the DP flow cytometer
and found that of samples with counts<350 cells/μl, 29% were misclassified as having>350
cells/μl by the Partec CyFlow Counter, and 7% of samples with CD4 counts>350 cells/μl were
misclassified downward as being<350 cells/μl [16].
Lutwama et al. conducted a large study of manual technologies in Uganda; they recruited
only HIV positive patients, the majority of whom had CD4 counts within the clinically impor-
tant range (range in study: 0–900 cells/μl) using the reference standard technology [18]. Of
samples with counts of<350 cells/μl using the reference standard technology, BC Cytospheres
misclassified only 1% as>350 cells/μl. However, of those with counts>350 cells/μl, 68% were
misclassified as<350 cells/μl (indicating that 68% of patients not qualifying for treatment
using the reference test would have done so if BC Cytospheres were used). Dynal Dynabeads
had upward and downward misclassification probabilities of 6% and 30% respectively.
Renault et al. (2010) conducted a comparison study between the Guava Easy CD4 and
FACSCount. Across a range of CD4 (0–1100 cells/μl), the upward and downward misclassifica-
tion was calculated and found to be 6.1% and 9.4%, respectively [27].
One study reported on evaluations of the PointCare NOW assay (this instrument has since
been re-marketed/rebranded as HumaCount CD4now (Human Diagnsotics Worldwide mbH,
Weisbaden, Germany) in five countries (Mozambique, Belgium, Canada, USA and South Af-
rica) [60]. Mozambique, Belgium, Canada and USA used the FACSCalibur as a reference stan-
dard while South Africa compared the PointCare NOW to the Epics XL. Upward and
downward misclassification were reported by country: Mozambique, +51%, -20%; Belgium,
+62%, -4%; Canada, +50%, -0%; USA, +0%, -3%; and for South Africa, +64%, -6%. Overall
misclassification was also calculated, and it was found that testing with PointCare NOW would
have led to 47% of patients with CD4 counts less than 350 cells/μl not eligible to receive treat-
ment (upward misclassification) and 6% of patients with CD4 counts greater than 350 cells/μl
eligible to receive treatment (downward misclassification).
Of the two studies evaluating the Pima Analyzer, Herbert et al. (2013) used the BC Cytomics
FC 500 as a reference standard while Jani et al. compared the Pima Analyzer to the BD FACS-
Calibur [56,61]. Across the clinically relevant range (60–1200 cells/μl), Herbert et al. found the
upward and downward misclassification to be 6.1% and 9.4% respectively. MBio Snap Count
was evaluated by Logan et al. (2013) and compared to the FACSCalibur [62]. Of the 94 sam-
ples, 2.1% were misclassified upward and 3.2% were misclassified downward at a threshold of
350 cells/μl.
Thirteen studies presented misclassification data using a CD4 cut-off of 200 cells/μl; these
are presented in Fig. 4b [12,13,15,17,18,20,23,28,36,56,60,61,63,64].
Even through misclassification probabilities can be influenced by the number of patients
with CD4 counts close to the threshold in each study, Pointcare NOW showed an overall
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tendancy towards upward misclassification at both thresholds of 200 and 350 cells/μl. Most
other technologies showed misclassification probabilities of<10%.
Precision
Forty-four percent of studies reported within-laboratory precision of absolute CD4 count
measurement, using replicates of fresh whole blood. [15,17,19,21,24,29,32–34,38–42,45–
47,50,54,56,58] Fig. 5 shows the inter- and intra assay variations expressed as % CV for the
Apogee Auto assay and the intra-assay variation for the mBio SnapCount [62,63].
Five studies reported between-laboratory precision using whole blood. Two were studies
evaluating BD FACSCount, [39,42] one evaluated Panleucogating, [50] and two were studies
evaluating bead-based SP technology (BD Trucount tubes and BC Flow-Count fluorospheres)
[46,47]. Gernow et al. studied the reproducibility of BC Cytospheres and found poor precision,
with a coefficient of variation of 58% [15]. The study by Landay et al., however, found precision
levels more in keeping with the other technologies [17].
Overall, in studies addressing between-laboratory precision, SP flow cytometry using BD
Trucount tubes or BC Flow-Count fluorospheres showed less inter-laboratory variability than
the DP comparators. [46,47] In addition, Denny et al. demonstrated improved inter-laboratory
precision using DP Panleucogating compared with technologies which included DP or SP con-
ventional flow cytometry [50]. External quality assurance data showed that the BD FACS-
Count, which is most commonly used a reference standard for CD4 assay evaluations, has
within-laboratory and between-laboratory precision of 15% or less [38,39,42,46].
Discussion
This review highlights the difficulties of answering clinically relevant questions about CD4 test
performance from the published literature. A minority of studies reported clinically useful
measures of accuracy, and few POC tests were carried out under field conditions.
It can be seen that whatever technology is chosen, there is variability associated with CD4
measurement. It should be noted that there is also significant physiological variability in CD4
count, that may account for as much as, if not more than, technical variability of CD4
Fig 5. Intra- and inter-assay variation (% CV) for the Apogee Auto 40 and for the MBio SnapCount at thresholds<350 cells/mL and>350 cells/mL.
doi:10.1371/journal.pone.0115019.g005
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measurement [65–67]. Performance characteristics vary between technologies and for the
same technology depending on the reference technology used as a comparator. These charac-
teristics have important implications both for individual patient management and for HIV
treatment programmes. It is essential to consider assay performance as well as operating char-
acteristics when choosing a technology. However, these data are not always available in the lit-
erature, and currently, evaluations are not sufficiently robust or comprehensive to give a clear
idea of the comparative merit of different technologies.
Misclassification probabilities describe the likelihood that a test will incorrectly categorise a
result as higher or lower than a given cut-off value as measured by a reference standard. They
are clinically relevant measures of accuracy, as they can be used to assess the likelihood that a
patient will be incorrectly classified above or below a defined CD4 threshold used in clinical de-
cision making. Misclassification probabilities for the same assay can vary not only because the
test is compared to different reference standards, but also because the probabilities are affected
by the number of samples clustered around the thresholds of 200 or 350 cells/ul.
Two types of misclassification can be defined—upward misclassification and downward
misclassification. Upward misclassification around a treatment threshold may be the most clin-
ically important, leading to a delay in starting ART in some patients, with potentially harmful
consequences. Downward misclassification on the other hand would be expected to lead to
ART use earlier than indicated, with potential implications for cost and drug exposure. Given
the trend towards earlier initiation in global and national guidelines, a degree of over-treatment
is likely to be preferred over significant under-treatment [68]. Furthermore, the use of CD4
counts alone to assess ART immunological failure in the absence of viral load monitoring will,
because of the biases observed, lead to some patients not receiving the appropriate
clinical intervention.
Misclassification data showed that manual technologies [18], particularly the method using
BC Cytospheres, were associated with substantial downward misclassification. It would there-
fore be expected that the implementation of these tests would lead to the decision to treat po-
tentially large numbers of additional patients who have CD4 counts above the guideline
threshold when using the reference test. Less upward misclassification was seen, suggesting
that under-treatment might be less of a problem with these technologies. Upward misclassifica-
tion by either manual technology is however likely to be an underestimate as the majority of
counts in this study were very low (less than 25% of samples had counts>200 cells/μl); if the
tests were to be used in a population with counts closer to the treatment threshold (as might be
the case if used primarily in asymptomatic patients), upwards misclassification would be ex-
pected to be higher.
Limited misclassification data were available for the Partec CyFlow instruments. Of con-
cern, one study evaluating the Partec CyFlow Counter under field conditions found 29% up-
ward misclassification; that is, 29% of patients potentially eligible for treatment may have been
denied treatment if the Partec CyFlow Counter-determined CD4 counts were the only criteria
for assessing eligibility [16]. No other studies of the Partec CyFlow Counter or other CyFlow
instruments reported misclassification probabilities at 350 cells/μl. Therefore, we do not know
if this finding was replicated elsewhere. The Guava PCA (using EasyCD4 reagents) and the
Pima Analyzer showed acceptable upward and downward misclassification rates.
There is some disparity in precision reported for the BC Cytospheres, and the reason for
this disparity is not clear. The CD4 counts of the 19 samples used for replicate analysis in the
study conducted by Gernow et al were not stated; however, they included 12 HIV negative
samples that might be assumed to have high counts [15]. Given that several papers found BC
Cytospheres to have poorer performance at higher counts, this may be in keeping with poor re-
producibility in these replicates. Another study, conducted by Landay et al., found better
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precision on a sample with a CD4 count of 1200 (%CV 35%) than on a sample with a CD4
count of 200 (%CV 108%) [17]. Manual methods, although employing simple technology, are
labor intensive and require significant user skill. Inadequate training, lack of supervision, or
user fatigue may lead to poor performance of these techniques. Neither study described the
training received by technicians performing the manual tests, nor reported blinding. Between-
laboratory precision is likely to be superior with SP technologies (using BD Trucount tubes or
BC Flow-Count fluorospheres) than with conventional DP technologies. As more point-of-
care devices are introduced to lower levels of the health system, where training and supervision
can be challenging, the lack of adequate training and supervision may introduce additional
sources of error, contributing to decreased assay precision. This should be addressed through
the development of a comprehensive training and supervision policy and implementation plan
for the introduction of POC devices. In addition to the studies presented in this review, evalua-
tions have been performed by government agencies and other national bodies that have not
been published in peer-reviewed journals. An evaluation of BC Cytospheres published by the
Medical Devices Agency of the UK included samples from 17 HIV positive subjects, and com-
pared BC Cytospheres against DP flow cytometry [69]. Accuracy was reported using assess-
ment of bias; misclassification probabilities were not reported. Imprecision was addressed
using 6–7 replicates of 6 samples, and found a CV range of 32–176% (mean 85%). Unpub-
lished evaluations have not been included in this review.
A recent review of external quality assurance (EQA) programmes involving 58,626 CD4
data sets from over 3,000 laboratories over a 12-year period show that SP technologies consis-
tently give lower relative errors and confidence limits than DP technologies at clinically signifi-
cant absolute CD4 counts [70].
Limitations of this review
Limitations include the fact that we only included papers published in the English language,
and we may have overlooked data because of this limitation. Limiting the search to the peer-re-
viewed literature may have overlooked robust evaluations conducted by national reference fa-
cilities or similar institutions.
It is important to consider that the reference standard technologies themselves are not per-
fect. Misclassification assumes that the reference result is accurate, i.e., the closest approxima-
tion to the truth. Thus, a result considered as a misclassification may in fact be correct. The
reference technology if performed once may give a result of 340cells/ul, but if performed in du-
plicate using the same specimen may give results of 340 and 360. It may be important for the
reference technology to be performed in duplicate and only when a concordant result is ob-
tained around a threshold of 350 can it be used as the reference standard for the new test.
What constitutes an “acceptable”margin of error and misclassification probabilities around
a threshold remain undefined and may vary among sites, depending on local factors such as the
distribution of CD4 counts among asymptomatic patients, how often patients undergo repeat
CD4 testing, and the implications of potential overtreatment (e.g., cost, long term risk of drug
toxicity). However, given the move towards earlier treatment and the use of better-tolerated, less
toxic drugs, misclassification that results in overtreatment may be more acceptable than would
have previously been the case. It is relatively straightforward for national programmes to decide
which technology best fits their needs based purely on cost and operating characteristics; it may
be harder to decide what performance characteristics are acceptable, and harder still to obtain
data on test performance to inform choice.
Given the potential for testing error, laboratory participation in EQA programmes and ac-
cess to quality control (QC) reagents are essential. EQA information is not mentioned in the
CD4 Assay Performance: A Systematic Review
PLOSONE | DOI:10.1371/journal.pone.0115019 March 19, 2015 21 / 26
publications included in the review. Without this information, the proficiency of the laboratory
staff performing the testing may have contributed to the errors and variation in addition to the
assays themselves.
Conclusions
A wide range of bias and percent misclassification around treatment thresholds over the clini-
cally relevant range were reported on the CD4 enumeration technologies included in this re-
view. Less than half the studies reporting assay precision or reproducibility of the CD4 values
obtained. This is a rapidly evolving field with new tests under development, and with existing
instruments and reagents being regularly replaced by updated versions. A systematic review of
POC tests compared to laboratory-based technologies showed that POC CD4 testing can in-
crease retention in care prior to treatment initiation and can also reduce time to eligibility as-
sessment resulting in more eligible patients being initiated on life-saving treatment [71]. The
lack of standardized methodology on test evaluation, including consensus on reference stan-
dards, is a barrier to assessing relative assay performance and could hinder the introduction of
new POC assays in countries where they are most needed.
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